Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended December 31, 2002 (Fiscal Year 2003).
Business Overview: The Company operates in four segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Dec 31, 2002 |
3 Months Ended Dec 31, 2001 |
6 Months Ended Dec 31, 2002 |
6 Months Ended Dec 31, 2001 |
|---|---|---|---|---|
| Operating Revenue | $12,706.3 | $11,221.7 | $24,122.9 | $21,087.1 |
| Operating Gross Margin | $1,079.5 | $1,000.5 | $2,086.4 | $1,915.2 |
| Operating Earnings | $590.9 | $469.7 | $1,058.4 | $869.7 |
| Net Earnings | $367.5 | $283.3 | $655.8 | $459.6 |
| Diluted EPS | $0.82 | $0.62 | $1.45 | $1.00 |
| Cash from Operations (6mo) | $358.9 | $(947.0) | ||
| Cash & Equivalents (End) | ||||
| Total Debt (Current + Long-term) | $2,260.0 (Dec 31, 2002) |
Note: Net earnings for the six months ended Dec 31, 2001 included a cumulative effect of change in accounting of $70.1 million.
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 13% for the quarter and 14% for the six-month period compared to the prior year. Growth was driven by higher sales volume, pharmaceutical price increases (~5%), new products, and acquisitions (specifically Magellan and BLP in the Pharmaceutical Technologies segment).
- Margin Compression: Overall gross margin percentage decreased to 8.50% (quarter) and 8.65% (six months) from 8.92% and 9.08% respectively. This was primarily due to a higher mix of lower-margin pharmaceutical distribution revenue and lower-margin distributed products in the Medical Products segment.
- Special Items Impact: The quarter included a net positive impact of $22.1 million from special items, driven largely by $89.9 million in litigation settlement income (antitrust claims against vitamin manufacturers). This offset $22.0 million in merger-related costs and $17.9 million in asset impairment/other charges.
- Cash Flow: Net cash provided by operating activities turned positive ($358.9 million) for the six months ended Dec 31, 2002, compared to a use of cash of $947.0 million in the prior year period. This improvement was due to better management of inventory and receivables relative to sales growth.
Guidance, Outlook, and Risks
- Future Costs: Management estimates approximately $80 million ($50 million net of tax) in additional merger-related, restructuring, and integration costs to be incurred primarily in fiscal 2003 and 2004.
- Acquisitions: On January 1, 2003, the Company completed the acquisition of Syncor International Corporation for approximately $781 million in stock plus $120 million in assumed debt. Syncor's operations will be integrated into the Pharmaceutical Technologies and Services segment.
- Share Repurchases: The Company completed a $500 million repurchase program in January 2003 and authorized a new $500 million program on January 28, 2003.
- Legal Risks:
- Latex Litigation: 314 pending lawsuits regarding natural rubber latex sensitization. Potential liability is estimated between $0 and $20 million net of insurance, though exact damages cannot be quantified.
- Syncor Litigation: Multiple shareholder class actions filed against Syncor alleging improper payments to foreign customers. The Company believes these will not have a material adverse effect.
- Accounting Changes: The Company adopted new FASB interpretations regarding variable interest entities and guarantees, though no material impact on financial position is anticipated.
Investor Verification Checklist
- Special Items Sustainability: Verify the non-recurring nature of the $92.8 million litigation settlement income and its impact on normalized earnings.
- Margin Trends: Monitor the mix of revenue between high-margin services and low-margin distribution to assess future gross margin stability.
- Integration Costs: Track the realization of the estimated $80 million in future merger and restructuring costs against actual quarterly expenses.
- Syncor Integration: Assess the financial impact and integration progress of the Syncor acquisition in subsequent filings.
- Inventory Levels: Review inventory build-up trends ($952.3 million increase in six months) to ensure it aligns with seasonal demand and does not signal future write-downs.